NO2914264T3 - - Google Patents

Info

Publication number
NO2914264T3
NO2914264T3 NO13776720A NO13776720A NO2914264T3 NO 2914264 T3 NO2914264 T3 NO 2914264T3 NO 13776720 A NO13776720 A NO 13776720A NO 13776720 A NO13776720 A NO 13776720A NO 2914264 T3 NO2914264 T3 NO 2914264T3
Authority
NO
Norway
Application number
NO13776720A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2914264T3 publication Critical patent/NO2914264T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO13776720A 2012-11-02 2013-10-04 NO2914264T3 (cg-RX-API-DMAC10.html)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12007494 2012-11-02
EP13776720.8A EP2914264B1 (en) 2012-11-02 2013-10-04 A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc)
PCT/EP2013/002998 WO2014067610A1 (en) 2012-11-02 2013-10-04 A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc)

Publications (1)

Publication Number Publication Date
NO2914264T3 true NO2914264T3 (cg-RX-API-DMAC10.html) 2018-01-06

Family

ID=47143496

Family Applications (1)

Application Number Title Priority Date Filing Date
NO13776720A NO2914264T3 (cg-RX-API-DMAC10.html) 2012-11-02 2013-10-04

Country Status (26)

Country Link
US (1) US20150283137A1 (cg-RX-API-DMAC10.html)
EP (1) EP2914264B1 (cg-RX-API-DMAC10.html)
JP (1) JP6255028B2 (cg-RX-API-DMAC10.html)
KR (1) KR102131588B1 (cg-RX-API-DMAC10.html)
CN (1) CN104768553A (cg-RX-API-DMAC10.html)
AR (1) AR093318A1 (cg-RX-API-DMAC10.html)
AU (1) AU2013339823B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015008279A2 (cg-RX-API-DMAC10.html)
CA (1) CA2890273C (cg-RX-API-DMAC10.html)
DK (1) DK2914264T3 (cg-RX-API-DMAC10.html)
ES (1) ES2646913T3 (cg-RX-API-DMAC10.html)
HK (1) HK1211869A1 (cg-RX-API-DMAC10.html)
HR (1) HRP20171295T1 (cg-RX-API-DMAC10.html)
HU (1) HUE035483T2 (cg-RX-API-DMAC10.html)
IL (1) IL238536B (cg-RX-API-DMAC10.html)
LT (1) LT2914264T (cg-RX-API-DMAC10.html)
MX (1) MX354518B (cg-RX-API-DMAC10.html)
NO (1) NO2914264T3 (cg-RX-API-DMAC10.html)
PL (1) PL2914264T3 (cg-RX-API-DMAC10.html)
PT (1) PT2914264T (cg-RX-API-DMAC10.html)
RS (1) RS56485B1 (cg-RX-API-DMAC10.html)
RU (1) RU2650679C2 (cg-RX-API-DMAC10.html)
SG (1) SG11201503214YA (cg-RX-API-DMAC10.html)
SI (1) SI2914264T1 (cg-RX-API-DMAC10.html)
WO (1) WO2014067610A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201503924B (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016002932B1 (pt) 2013-08-14 2021-02-23 Yugenkaisha Japan Tsusyo sistema de cultivo hidropônico
HRP20231548T1 (hr) * 2019-07-10 2024-03-15 Merck Patent Gmbh Farmaceutski pripravak
EP4045009A4 (en) 2019-10-14 2023-11-01 Olatec Therapeutics LLC METHOD FOR TREATING BREAST CANCER

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005057924A1 (de) * 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
CA2949515C (en) * 2009-01-08 2018-10-23 Axel Becker Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof

Also Published As

Publication number Publication date
CN104768553A (zh) 2015-07-08
MX2015005265A (es) 2015-07-17
MX354518B (es) 2018-03-08
RS56485B1 (sr) 2018-01-31
RU2015120692A (ru) 2016-12-27
JP2015536957A (ja) 2015-12-24
CA2890273A1 (en) 2014-05-08
ZA201503924B (en) 2020-11-25
DK2914264T3 (en) 2017-09-11
SG11201503214YA (en) 2015-05-28
EP2914264B1 (en) 2017-08-09
IL238536A0 (en) 2015-06-30
HK1211869A1 (en) 2016-06-03
EP2914264A1 (en) 2015-09-09
BR112015008279A2 (pt) 2017-07-04
KR20150079942A (ko) 2015-07-08
SI2914264T1 (sl) 2017-12-29
PL2914264T3 (pl) 2017-12-29
AR093318A1 (es) 2015-05-27
HRP20171295T1 (hr) 2017-10-20
ES2646913T3 (es) 2017-12-18
RU2650679C2 (ru) 2018-04-17
KR102131588B1 (ko) 2020-07-08
LT2914264T (lt) 2017-11-10
IL238536B (en) 2019-01-31
AU2013339823A1 (en) 2015-06-18
US20150283137A1 (en) 2015-10-08
WO2014067610A1 (en) 2014-05-08
AU2013339823B2 (en) 2018-01-04
HUE035483T2 (hu) 2018-05-02
CA2890273C (en) 2021-10-26
PT2914264T (pt) 2017-11-14
JP6255028B2 (ja) 2017-12-27

Similar Documents

Publication Publication Date Title
BR112014017625A2 (cg-RX-API-DMAC10.html)
BR112014017659A2 (cg-RX-API-DMAC10.html)
BR112014017607A2 (cg-RX-API-DMAC10.html)
BR112014024833A2 (cg-RX-API-DMAC10.html)
BR112014017592A2 (cg-RX-API-DMAC10.html)
BR112014017646A2 (cg-RX-API-DMAC10.html)
BR112014017638A2 (cg-RX-API-DMAC10.html)
AR092201A1 (cg-RX-API-DMAC10.html)
BR112013027865A2 (cg-RX-API-DMAC10.html)
BR112014017644A2 (cg-RX-API-DMAC10.html)
BR112014018300A2 (cg-RX-API-DMAC10.html)
BR112014017634A2 (cg-RX-API-DMAC10.html)
BR112014017647A2 (cg-RX-API-DMAC10.html)
BR112014013184A8 (cg-RX-API-DMAC10.html)
BR112014017618A2 (cg-RX-API-DMAC10.html)
BR112014018782A2 (cg-RX-API-DMAC10.html)
BR112014017627A2 (cg-RX-API-DMAC10.html)
BR112014017623A2 (cg-RX-API-DMAC10.html)
BR112014017652A2 (cg-RX-API-DMAC10.html)
BR112014019282A2 (cg-RX-API-DMAC10.html)
BR112014017630A2 (cg-RX-API-DMAC10.html)
BR112014017621A2 (cg-RX-API-DMAC10.html)
BR112014017631A2 (cg-RX-API-DMAC10.html)
BR112014017808A2 (cg-RX-API-DMAC10.html)
BR112014017989A2 (cg-RX-API-DMAC10.html)